RANKL (soluble) Antibody 500-P133-1MG from Thermo Fisher Scientific

81 Wyman Street

Waltham, MA 02451

United States

Phone: 800-678-5599
Fax: 800-331-2286

(1) Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancerOncotargetMay 12, 2020Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, et al.

(2) RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritisArthritis research & therapyJune 18, 2012Martínez-Calatrava MJ, Prieto-Potín I, Roman-Blas JA, Tardio L, Largo R, Herrero-Beaumont G.

(4) Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survivalThe Journal of biological chemistryNovember 13, 2009Baud'huin M, Duplomb L, Téletchéa S, Charrier C, Maillasson M, Fouassier M, Heymann D.

(5) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysisThe American journal of pathologyNovember 1, 2003Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D.

(6) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the boneThe Journal of clinical investigationMay 1, 2001Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET.

WB